



## Clinical trial results:

### Placebo-controlled efficacy and safety trial of intravenous neridronic acid in subjects with complex regional pain syndrome (CRPS)

#### Summary

EudraCT number	2017-004244-37
Trial protocol	CZ SK
Global end of trial date	01 August 2019

#### Results information

Result version number	v1 (current)
This version publication date	25 July 2020
First version publication date	25 July 2020

#### Trial information

##### Trial identification

Sponsor protocol code	KF7013-04
-----------------------	-----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03560986
WHO universal trial number (UTN)	U1111-1203-5020

Notes:

##### Sponsors

Sponsor organisation name	Grünenthal GmbH
Sponsor organisation address	Zieglerstrasse 6, Aachen, Germany, 52076
Public contact	Grünenthal Trial Information Desk, Grünenthal GmbH, 49 2415693223, Clinical-Trials@grunenthal.com
Scientific contact	Grünenthal Trial Information Desk, Grünenthal GmbH, 49 2415693223, Clinical-Trials@grunenthal.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 December 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	01 August 2019
Global end of trial reached?	Yes
Global end of trial date	01 August 2019
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To demonstrate the superior efficacy of a cumulative dose of 400 mg intravenous neridronic acid versus placebo for the treatment of CRPS-related pain.

Protection of trial subjects:

The trial was conducted according to ICH-GCP guidelines, the applicable local laws and regulations, and in accordance with the ethical principles that have their origins in the Declaration of Helsinki. Regulatory authorities were notified of the trial as required by national regulations, and where necessary relevant authorization was obtained.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	31 May 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 7
Country: Number of subjects enrolled	United States: 180
Country: Number of subjects enrolled	Serbia: 6
Country: Number of subjects enrolled	Poland: 3
Country: Number of subjects enrolled	Slovakia: 19
Country: Number of subjects enrolled	United Kingdom: 31
Country: Number of subjects enrolled	Czech Republic: 21
Worldwide total number of subjects	267
EEA total number of subjects	74

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	233
From 65 to 84 years	34
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The first subject was enrolled on 31 May 2018, the last subject's last assessment was on 01 Aug 2019. After a pooled interim analysis of primary endpoint data of trials KF7013-04 and KF7013-02, recruitment was stopped as interim results indicated futility (neridronic acid unlikely to be statistically significantly superior to Placebo).

### Pre-assignment

Screening details:

267 subjects were enrolled (signed consent), 100 were allocated to treatment, and 99 received neridronate or placebo. Of 167 subjects not allocated, 99 did not meet inclusion/met exclusion criteria, 3 were lost to follow-up, 14 withdrew consent, 1 experienced adverse events, and 50 were not allocated for other reasons (trial termination)

### Period 1

Period 1 title	Treatment Period A/Follow-up Period 1
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Assessor

Blinding implementation details:

Blinded treatment with neridronic acid or placebo in Treatment Period A.

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Baseline to Week 26: Neridronic Acid TPA
------------------	--

Arm description:

In Treatment Period A (TPA), subjects received neridronic acid 100 mg - 4 intravenous infusions within 10 days; Follow-up Period 1 until 26 weeks.

Arm type	Experimental
Investigational medicinal product name	Neridronic acid
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Neridronic acid 400 mg administered by 4 intravenous infusions within 10 Days.

<b>Arm title</b>	Baseline to Week 26: Placebo TPA
------------------	----------------------------------

Arm description:

In Treatment Period A (TPA), subjects received matching placebo - 4 intravenous infusions within 10 Days; Follow-up Period 1 until 26 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Matching placebo was administered by 4 intravenous infusions within 10 Days.

Number of subjects in period 1[1]	Baseline to Week 26: Neridronic Acid TPA	Baseline to Week 26: Placebo TPA
	Started	48
Treatment Period A completers	45	45
Follow-up Period 1 completers	12	13
Completed	12	13
Not completed	36	38
Various reasons (mainly trial termination)	36	38

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 267 participants were enrolled (signed consent), 100 were allocated to treatment, and 99 received trial medication. Baseline characteristics are reported for subjects who received trial medication.

## Period 2

Period 2 title	Treatment Period B/Follow-up Period 2
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Week 26-52: Neridronic acid TPA, Neridronic acid TPB

Arm description:

Subjects who had completed treatment with neridronic acid in Treatment Period A/Follow-up Period 1 received re-treatment with neridronic acid 100 mg - 4 intravenous infusions within 10 days in Treatment Period B (TPB) with a Follow-up Period 2 until 52 weeks. Infusions in Treatment Period B were not blinded.

Three of 12 subjects who completed Treatment Period A/Follow-up Period 1 were not allocated to treatment with neridronic acid in Treatment Period B.

Arm type	Experimental
Investigational medicinal product name	Neridronic acid
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Neridronic acid 400 mg administered by 4 intravenous infusions within 10 Days (open-label infusions)

<b>Arm title</b>	Week 26-52: Placebo TPA, Neridronic acid TPB
------------------	--

Arm description:

Subjects who had completed treatment with placebo in Treatment Period A/Follow-up Period 1 received neridronic acid treatment (100 mg - 4 intravenous infusions within 10 days) in Treatment Period B (TPB) with a Follow-up Period 2 until 52 weeks. Infusions in Treatment Period B were not blinded.

Five of 13 subjects who completed treatment with placebo in Treatment Period A/Follow-up Period 1 were not allocated to treatment with neridronic acid in Treatment Period B.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Neridronic acid
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use
Dosage and administration details: Neridronic acid 400 mg administered by 4 intravenous infusions within 10 Days.	
<b>Arm title</b>	Week 26 to Week 52: Placebo TPA
Arm description: Subjects with placebo treatment in Treatment Period A/Follow-up Period 1 were followed up without administration of trial medication until 52 weeks in Follow-up Period 2.	
Arm type	No intervention
No investigational medicinal product assigned in this arm	
<b>Arm title</b>	Week 26 to Week 52: Neridronic Acid TPA
Arm description: Subjects who had completed treatment with neridronic acid treatment in Treatment Period A/Follow-up Period 1 were followed up without administration of trial medication until 52 weeks in Follow-up Period 2.	
Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 2	Week 26-52: Neridronic acid TPA, Neridronic acid TPB	Week 26-52: Placebo TPA, Neridronic acid TPB	Week 26 to Week 52: Placebo TPA
	Started	9	8
Treatment Period B completers	8	8	0
Completed	1	0	0
Not completed	8	8	5
Consent withdrawn by subject	-	1	-
Adverse event, non-fatal	1	-	-
Discontinued before end of Follow-up Period 2	7	7	-
Various reasons (mainly trial termination)	-	-	5

Number of subjects in period 2	Week 26 to Week 52: Neridronic Acid TPA
Started	3
Treatment Period B completers	0
Completed	0
Not completed	3
Consent withdrawn by subject	-
Adverse event, non-fatal	-
Discontinued before end of Follow-up Period 2	-
Various reasons (mainly trial termination)	3



## Baseline characteristics

### Reporting groups

Reporting group title	Baseline to Week 26: Neridronic Acid TPA
Reporting group description:	In Treatment Period A (TPA), subjects received neridronic acid 100 mg - 4 intravenous infusions within 10 days; Follow-up Period 1 until 26 weeks.
Reporting group title	Baseline to Week 26: Placebo TPA
Reporting group description:	In Treatment Period A (TPA), subjects received matching placebo - 4 intravenous infusions within 10 Days; Follow-up Period 1 until 26 weeks.

Reporting group values	Baseline to Week 26: Neridronic Acid TPA	Baseline to Week 26: Placebo TPA	Total
Number of subjects	48	51	99
Age categorical			
Units: Subjects			
Adults (18-64 years)	42	46	88
From 65-84 years	6	5	11
Age continuous			
Units: years			
arithmetic mean	49.5	50.4	
standard deviation	± 12.7	± 12.6	-
Gender categorical			
Units: Subjects			
Female	35	36	71
Male	13	15	28
Race			
Units: Subjects			
American Indian or Alaska Native	2	1	3
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	3	6	9
White	42	44	86
More than one race	1	0	1
Unknown or Not Reported	0	0	0
CRPS type			
Units: Subjects			
Type I	38	33	71
Type II	5	9	14
Unknown	5	9	14
Time since onset of CRPS symptoms			
Units: months			
median	12.88	11.80	
inter-quartile range (Q1-Q3)	7.30 to 18.90	6.00 to 18.57	-
Time since diagnosis of CRPS			
Units: months			
median	5.92	5.83	
inter-quartile range (Q1-Q3)	0.87 to 11.03	0.03 to 15.03	-



## End points

### End points reporting groups

Reporting group title	Baseline to Week 26: Neridronic Acid TPA
Reporting group description:	In Treatment Period A (TPA), subjects received neridronic acid 100 mg - 4 intravenous infusions within 10 days; Follow-up Period 1 until 26 weeks.
Reporting group title	Baseline to Week 26: Placebo TPA
Reporting group description:	In Treatment Period A (TPA), subjects received matching placebo - 4 intravenous infusions within 10 Days; Follow-up Period 1 until 26 weeks.
Reporting group title	Week 26-52: Neridronic acid TPA, Neridronic acid TPB
Reporting group description:	Subjects who had completed treatment with neridronic acid in Treatment Period A/Follow-up Period 1 received re-treatment with neridronic acid 100 mg - 4 intravenous infusions within 10 days in Treatment Period B (TPB) with a Follow-up Period 2 until 52 weeks. Infusions in Treatment Period B were not blinded.  Three of 12 subjects who completed Treatment Period A/Follow-up Period 1 were not allocated to treatment with neridronic acid in Treatment Period B.
Reporting group title	Week 26-52: Placebo TPA, Neridronic acid TPB
Reporting group description:	Subjects who had completed treatment with placebo in Treatment Period A/Follow-up Period 1 received neridronic acid treatment (100 mg - 4 intravenous infusions within 10 days) in Treatment Period B (TPB) with a Follow-up Period 2 until 52 weeks. Infusions in Treatment Period B were not blinded.  Five of 13 subjects who completed treatment with placebo in Treatment Period A/Follow-up Period 1 were not allocated to treatment with neridronic acid in Treatment Period B.
Reporting group title	Week 26 to Week 52: Placebo TPA
Reporting group description:	Subjects with placebo treatment in Treatment Period A/Follow-up Period 1 were followed up without administration of trial medication until 52 weeks in Follow-up Period 2.
Reporting group title	Week 26 to Week 52: Neridronic Acid TPA
Reporting group description:	Subjects who had completed treatment with neridronic acid treatment in Treatment Period A/Follow-up Period 1 were followed up without administration of trial medication until 52 weeks in Follow-up Period 2.

### Primary: Change From Baseline to Week 12 in the Average Pain Intensity Score (Weekly Average of Pain Values Recorded Daily in the Electronic Diary)

End point title	Change From Baseline to Week 12 in the Average Pain Intensity Score (Weekly Average of Pain Values Recorded Daily in the Electronic Diary)
End point description:	In the Baseline Phase and in Treatment Period A/Follow-up Period 1, subjects were asked to assessed their average CRPS-related pain on an 11-point numerical rating scale (NRS) - from 0 = "no pain" to 10 = "pain as bad as you can imagine" and report it once daily (in the evening, 24-hour recall) in an electronic diary. Changes from baseline (average for the Baseline Phase) to the weekly average for Week 12 were calculated for the Full Analysis Set, i.e., all subjects treated in Treatment Period A with all data available at the time of last subject out following premature trial termination.
End point type	Primary
End point timeframe:	From the Baseline Phase (Day -7 to Day -1) to Week 12

<b>End point values</b>	Baseline to Week 26: Neridronic Acid TPA	Baseline to Week 26: Placebo TPA		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	48	51		
Units: Units on a scale				
least squares mean (standard error)	-1.28 (± 0.270)	-1.71 (± 0.268)		

## Statistical analyses

<b>Statistical analysis title</b>	Superiority testing
-----------------------------------	---------------------

Statistical analysis description:

Mixed-effects model for repeated measures (MMRM) defined with baseline pain intensity as covariate, the factors geographic region, week, treatment and treatment-by-week as fixed effects, and an unstructured covariance matrix to model the covariance structure of the repeated measurements.

Comparison groups	Baseline to Week 26: Placebo TPA v Baseline to Week 26: Neridronic Acid TPA
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2522 <sup>[1]</sup>
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	0.43
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.31
upper limit	1.17
Variability estimate	Standard error of the mean
Dispersion value	0.372

Notes:

[1] - 2-sided p-value for testing superiority of neridronic acid 400 mg compared to placebo.

## Secondary: Change From Baseline to Week 26 in the Average Pain Intensity Recorded on the Tablet Computer

End point title	Change From Baseline to Week 26 in the Average Pain Intensity Recorded on the Tablet Computer
-----------------	---

End point description:

11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall). Changes from baseline to Week 26 were planned to be analyzed.

Secondary endpoints were not analyzed because the trial was terminated prematurely following a pooled interim analysis of primary endpoint data of trials KF7013-04 and KF7013-02 (EudraCT 2016-003833-91).

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Visit 2 [Day 1]) to Visit 11 (Week 26).

<b>End point values</b>	Baseline to Week 26: Neridronic Acid TPA	Baseline to Week 26: Placebo TPA		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[2]</sup>	0 <sup>[3]</sup>		
Units: Units on a scale				
arithmetic mean (standard deviation)	( )	( )		

Notes:

[2] - No analysis performed

[3] - No analysis performed.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Pain Response to Treatment, Defined as at Least 30% Decrease from Baseline in the Average Pain Intensity at Week 12, Recorded on the Tablet Computer

End point title	Pain Response to Treatment, Defined as at Least 30% Decrease from Baseline in the Average Pain Intensity at Week 12, Recorded on the Tablet Computer
-----------------	--

End point description:

11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall).

The number of subjects with response at Week 12 was planned to be determined.

Secondary endpoints were not analyzed because the trial was terminated prematurely following a pooled interim analysis of primary endpoint data of trials KF7013-04 and KF7013-02 (EudraCT 2016-003833-91).

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)

<b>End point values</b>	Baseline to Week 26: Neridronic Acid TPA	Baseline to Week 26: Placebo TPA		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[4]</sup>	0 <sup>[5]</sup>		
Units: Number of subjects				

Notes:

[4] - No analysis performed.

[5] - No analysis performed.

### Statistical analyses

No statistical analyses for this end point

---

**Secondary: Pain Response to Treatment, Defined as at Least 30% Decrease from Baseline in the Average Pain Intensity at Week 26, Recorded on the Tablet Computer**

---

End point title	Pain Response to Treatment, Defined as at Least 30% Decrease from Baseline in the Average Pain Intensity at Week 26, Recorded on the Tablet Computer
-----------------	--

End point description:

11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall).

The number of subjects with response at Week 26 was planned to be determined.

Secondary endpoints were not analyzed because the trial was terminated prematurely following a pooled interim analysis of primary endpoint data of trials KF7013-04 and KF7013-02 (EudraCT 2016-003833-91).

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Visit 2 [Day 1]) to Visit 11 (Week 26)

---

End point values	Baseline to Week 26: Neridronic Acid TPA	Baseline to Week 26: Placebo TPA		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[6]</sup>	0 <sup>[7]</sup>		
Units: Number of subjects				

Notes:

[6] - No analysis performed.

[7] - No analysis performed.

---

**Statistical analyses**

---

No statistical analyses for this end point

---

---

**Secondary: Change From Baseline to Week 12 in the Pain Intensity Level of Dynamic Mechanical Allodynia (DMA)**

---

End point title	Change From Baseline to Week 12 in the Pain Intensity Level of Dynamic Mechanical Allodynia (DMA)
-----------------	---

End point description:

Dynamic Mechanical Allodynia: a Tactile Stimulus is Applied in a Single Sweeping Motion (1 cm to 2 cm Length) on the Skin on the Affected Limb. The subjects were asked to judge the stimulus intensity by means of an NRS (0 to 10). "0" in this case means "no pain". Each "pricking", "stinging" or "burning" sensation is defined as a painful sensation, which should always be evaluated by giving a value greater than "0". "10" corresponds to the individual maximum pain imaginable. Changes from baseline to Week 12 were planned to be analyzed.

Secondary endpoints were not analyzed because the trial was terminated prematurely following a pooled interim analysis of primary endpoint data of trials KF7013-04 and KF7013-02 (EudraCT 2016-003833-91).

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)

---

<b>End point values</b>	Baseline to Week 26: Neridronic Acid TPA	Baseline to Week 26: Placebo TPA		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[8]</sup>	0 <sup>[9]</sup>		
Units: Units on a scale				
arithmetic mean (standard deviation)	( )	( )		

Notes:

[8] - No analysis performed.

[9] - No analysis performed.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline to Week 12 in the Pressure Pain Threshold (PPT) Ratio for the Thenar Muscle/Abductor Hallucis Muscle

End point title	Change From Baseline to Week 12 in the Pressure Pain Threshold (PPT) Ratio for the Thenar Muscle/Abductor Hallucis Muscle
-----------------	---

End point description:

Pressure pain threshold: using a pressure algometer (contact area 1 cm<sup>2</sup>), the threshold for pressure-induced pain is measured on the thenar muscle/abductor hallucis muscle in 3 series of slowly increasing stimulus intensities (at a rate of about 50 kPa/s). The threshold is then determined as the arithmetic mean of the 3 series (in kPa).

The ratio of the thresholds of the affected limb versus the unaffected limb was planned to be calculated and used for the determination of the change from baseline.

Secondary endpoints were not analyzed because the trial was terminated prematurely following a pooled interim analysis of primary endpoint data of trials KF7013-04 and KF7013-02 (EudraCT 2016-003833-91).

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)

<b>End point values</b>	Baseline to Week 26: Neridronic Acid TPA	Baseline to Week 26: Placebo TPA		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[10]</sup>	0 <sup>[11]</sup>		
Units: Ratio				
arithmetic mean (standard deviation)	( )	( )		

Notes:

[10] - No analysis performed.

[11] - No analysis performed.

### Statistical analyses

No statistical analyses for this end point

---

**Secondary: Change From Baseline to Week 12 in the Ratio of the Figure of Eight Measurements of the Affected Limb Versus the Unaffected Limb**

---

End point title	Change From Baseline to Week 12 in the Ratio of the Figure of Eight Measurements of the Affected Limb Versus the Unaffected Limb
-----------------	--

End point description:

In subjects with the CRPS sign of edema on the CRPS severity score at baseline, circumference of the hand or foot will be measured by the investigator with measurement tape using the figure-of-eight method at both the affected limb and the contralateral unaffected limb. Each measurement will be performed 3 times. The average of the 3 measurements will be used for further analysis. The ratio of the averages of the affected limb versus the unaffected limb was planned to be calculated and used for the determination of the change from baseline.

Secondary endpoints were not analyzed because the trial was terminated prematurely following a pooled interim analysis of primary endpoint data of trials KF7013-04 and KF7013-02 (EudraCT 2016-003833-91).

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)

---

<b>End point values</b>	Baseline to Week 26: Neridronic Acid TPA	Baseline to Week 26: Placebo TPA		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[12]</sup>	0 <sup>[13]</sup>		
Units: Ratio				
arithmetic mean (standard deviation)	( )	( )		

Notes:

[12] - No analysis performed.

[13] - No analysis performed.

---

**Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events were documented from the time of enrollment (i.e., the time the informed consent form was signed) up to the time of the last protocol scheduled contact, i.e., date of last visit/contact (could be a phone call, e.g., in case of withdrawal).

Adverse event reporting additional description:

Only treatment emergent adverse events (TEAEs) reported after first administration of trial medication are reported. Subjects with TEAEs may be presented in 2 of 6 reporting groups depending on the time the TEAEs were reported.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.0
--------------------	------

### Reporting groups

Reporting group title	Baseline to Week 26: Placebo TPA
-----------------------	----------------------------------

Reporting group description:

In Treatment Period A (TPA), subjects received matching placebo - 4 intravenous infusions within 10 days; Follow-up Period 1 until 26 weeks.

Reporting group title	Baseline to Week 26: Neridronic acid TPA
-----------------------	--

Reporting group description:

In Treatment Period A (TPA), subjects received neridronic acid 100 mg - 4 intravenous infusions within 10 Days; Follow-up Period 1 until 26 weeks.

Reporting group title	Week 26 to Week 52: Placebo TPA
-----------------------	---------------------------------

Reporting group description:

Subjects with placebo treatment in Treatment Period A/Follow-up Period 1 were followed up without administration of trial medication until 52 weeks in Follow-up Period 2.

Reporting group title	Week 26 to Week 52: Placebo TPA, Neridronic Acid TPB
-----------------------	--

Reporting group description:

Subjects who had completed treatment with placebo in Treatment Period A/Follow-up Period 1 received neridronic acid treatment (100 mg - 4 intravenous infusions within 10 days) in Treatment Period B (TPB) with a Follow-up Period 2 until 52 weeks.

Reporting group title	Week 26 to Week 52: Neridronic Acid TPA
-----------------------	---

Reporting group description:

Subjects who had completed treatment with neridronic acid treatment in Treatment Period A/Follow-up Period 1 were followed up without administration of trial medication until 52 weeks in Follow-up Period 2.

Reporting group title	Week 26 to Week 52: Neridronic Acid TPA, Neridronic Acid TPB
-----------------------	--

Reporting group description:

Subjects who had completed treatment with neridronic acid in Treatment Period A/Follow-up Period 1 received re-treatment with neridronic acid 100 mg - 4 intravenous infusions within 10 days in Treatment Period B (TPB) with a Follow-up Period 2 until 52 weeks.

<b>Serious adverse events</b>	Baseline to Week 26: Placebo TPA	Baseline to Week 26: Neridronic acid TPA	Week 26 to Week 52: Placebo TPA
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 51 (5.88%)	2 / 48 (4.17%)	0 / 43 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 51 (0.00%)	0 / 48 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	1 / 51 (1.96%)	0 / 48 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Silent myocardial infarction			
subjects affected / exposed	0 / 51 (0.00%)	1 / 48 (2.08%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Dysaesthesia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 48 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Retinal detachment			
subjects affected / exposed	1 / 51 (1.96%)	0 / 48 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 51 (0.00%)	1 / 48 (2.08%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 51 (0.00%)	1 / 48 (2.08%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			

Decreased appetite			
subjects affected / exposed	1 / 51 (1.96%)	0 / 48 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Week 26 to Week 52: Placebo TPA, Neridronic Acid TPB	Week 26 to Week 52: Neridronic Acid TPA	Week 26 to Week 52: Neridronic Acid TPA, Neridronic Acid TPB
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	1 / 8 (12.50%)	0 / 39 (0.00%)	1 / 9 (11.11%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
<b>Injury, poisoning and procedural complications</b>			
<b>Fall</b>			
subjects affected / exposed	1 / 8 (12.50%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Overdose</b>			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardiac disorders</b>			
<b>Silent myocardial infarction</b>			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorders</b>			
<b>Dysaesthesia</b>			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Eye disorders</b>			
<b>Retinal detachment</b>			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Renal and urinary disorders Nephrolithiasis subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations Urinary tract infection subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 2 %

<b>Non-serious adverse events</b>	Baseline to Week 26: Placebo TPA	Baseline to Week 26: Neridronic acid TPA	Week 26 to Week 52: Placebo TPA
Total subjects affected by non-serious adverse events subjects affected / exposed	40 / 51 (78.43%)	40 / 48 (83.33%)	1 / 43 (2.33%)
Vascular disorders Hypertension subjects affected / exposed	1 / 51 (1.96%)	2 / 48 (4.17%)	0 / 43 (0.00%)
occurrences (all)	1	2	0
General disorders and administration site conditions Acute phase reaction subjects affected / exposed	5 / 51 (9.80%)	8 / 48 (16.67%)	0 / 43 (0.00%)
occurrences (all)	6	10	0
Fatigue subjects affected / exposed	1 / 51 (1.96%)	3 / 48 (6.25%)	0 / 43 (0.00%)
occurrences (all)	1	3	0
Influenza like illness subjects affected / exposed	0 / 51 (0.00%)	4 / 48 (8.33%)	0 / 43 (0.00%)
occurrences (all)	0	4	0

Oedema peripheral subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	2 / 48 (4.17%) 2	0 / 43 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	3 / 48 (6.25%) 3	0 / 43 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	1 / 48 (2.08%) 1	0 / 43 (0.00%) 0
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 48 (0.00%) 0	0 / 43 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	0 / 48 (0.00%) 0	0 / 43 (0.00%) 0
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	2 / 48 (4.17%) 2	0 / 43 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	1 / 48 (2.08%) 1	0 / 43 (0.00%) 0
Investigations Lipase increased subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	3 / 48 (6.25%) 3	0 / 43 (0.00%) 0
Urine albumin/creatinine ratio increased subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	5 / 48 (10.42%) 5	0 / 43 (0.00%) 0
Blood immunoglobulin D decreased subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 48 (0.00%) 0	0 / 43 (0.00%) 0
Injury, poisoning and procedural complications			

Fall subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 48 (2.08%) 1	0 / 43 (0.00%) 0
Radius fracture subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 48 (0.00%) 0	0 / 43 (0.00%) 0
<b>Nervous system disorders</b>			
Complex regional pain syndrome subjects affected / exposed occurrences (all)	3 / 51 (5.88%) 4	1 / 48 (2.08%) 1	0 / 43 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	3 / 51 (5.88%) 3	1 / 48 (2.08%) 1	0 / 43 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	5 / 51 (9.80%) 8	3 / 48 (6.25%) 3	0 / 43 (0.00%) 0
Paraesthesia subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	2 / 48 (4.17%) 3	0 / 43 (0.00%) 0
Taste disorder subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	0 / 48 (0.00%) 0	0 / 43 (0.00%) 0
<b>Blood and lymphatic system disorders</b>			
Anaemia subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 48 (0.00%) 0	0 / 43 (0.00%) 0
<b>Eye disorders</b>			
Eye pain subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 48 (0.00%) 0	0 / 43 (0.00%) 0
<b>Gastrointestinal disorders</b>			
Diarrhoea subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	2 / 48 (4.17%) 2	0 / 43 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	8 / 51 (15.69%) 12	2 / 48 (4.17%) 2	0 / 43 (0.00%) 0

Vomiting subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	0 / 48 (0.00%) 0	0 / 43 (0.00%) 0
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 48 (0.00%) 0	0 / 43 (0.00%) 0
Renal and urinary disorders Renal pain subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 48 (0.00%) 0	0 / 43 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	3 / 51 (5.88%) 3	3 / 48 (6.25%) 3	0 / 43 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	3 / 48 (6.25%) 4	0 / 43 (0.00%) 0
Bone pain subjects affected / exposed occurrences (all)	3 / 51 (5.88%) 5	1 / 48 (2.08%) 1	0 / 43 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	2 / 48 (4.17%) 3	0 / 43 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	3 / 48 (6.25%) 3	0 / 43 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	4 / 48 (8.33%) 8	0 / 43 (0.00%) 0
Tendonitis subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	0 / 48 (0.00%) 0	0 / 43 (0.00%) 0
Infections and infestations Laryngitis			

subjects affected / exposed	2 / 51 (3.92%)	0 / 48 (0.00%)	0 / 43 (0.00%)
occurrences (all)	2	0	0
<b>Nasopharyngitis</b>			
subjects affected / exposed	2 / 51 (3.92%)	2 / 48 (4.17%)	0 / 43 (0.00%)
occurrences (all)	2	2	0
<b>Sinusitis</b>			
subjects affected / exposed	0 / 51 (0.00%)	2 / 48 (4.17%)	0 / 43 (0.00%)
occurrences (all)	0	2	0
<b>Urinary tract infection</b>			
subjects affected / exposed	1 / 51 (1.96%)	4 / 48 (8.33%)	0 / 43 (0.00%)
occurrences (all)	1	4	0
<b>Viral upper respiratory tract infection</b>			
subjects affected / exposed	1 / 51 (1.96%)	2 / 48 (4.17%)	0 / 43 (0.00%)
occurrences (all)	1	2	0
<b>Abscess neck</b>			
subjects affected / exposed	0 / 51 (0.00%)	0 / 48 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
<b>Cellulitis</b>			
subjects affected / exposed	0 / 51 (0.00%)	0 / 48 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
<b>Clostridium difficile infection</b>			
subjects affected / exposed	0 / 51 (0.00%)	0 / 48 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
<b>Lyme disease</b>			
subjects affected / exposed	0 / 51 (0.00%)	0 / 48 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
<b>Infection protozoal</b>			
subjects affected / exposed	0 / 51 (0.00%)	0 / 48 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
<b>Pneumonia</b>			
subjects affected / exposed	0 / 51 (0.00%)	0 / 48 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
<b>Diverticulitis</b>			
subjects affected / exposed	1 / 51 (1.96%)	0 / 48 (0.00%)	1 / 43 (2.33%)
occurrences (all)	1	0	1
<b>Metabolism and nutrition disorders</b>			

Hyperglycaemia subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 4	1 / 48 (2.08%) 1	0 / 43 (0.00%) 0
Vitamin D deficiency subjects affected / exposed occurrences (all)	5 / 51 (9.80%) 5	3 / 48 (6.25%) 3	0 / 43 (0.00%) 0

<b>Non-serious adverse events</b>	Week 26 to Week 52: Placebo TPA, Neridronic Acid TPB	Week 26 to Week 52: Neridronic Acid TPA	Week 26 to Week 52: Neridronic Acid TPA, Neridronic Acid TPB
Total subjects affected by non-serious adverse events subjects affected / exposed	6 / 8 (75.00%)	0 / 39 (0.00%)	5 / 9 (55.56%)
Vascular disorders			
Hypertension subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
General disorders and administration site conditions			
Acute phase reaction subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 9	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
Influenza like illness subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
Oedema peripheral subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
Immune system disorders			

Hypersensitivity subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 39 (0.00%) 0	1 / 9 (11.11%) 1
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)  Insomnia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0  0 / 8 (0.00%) 0	0 / 39 (0.00%) 0  0 / 39 (0.00%) 0	0 / 9 (0.00%) 0  0 / 9 (0.00%) 0
Investigations Lipase increased subjects affected / exposed occurrences (all)  Urine albumin/creatinine ratio increased subjects affected / exposed occurrences (all)  Blood immunoglobulin D decreased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0  0 / 8 (0.00%) 0  1 / 8 (12.50%) 1	0 / 39 (0.00%) 0  0 / 39 (0.00%) 0  0 / 39 (0.00%) 0	0 / 9 (0.00%) 0  0 / 9 (0.00%) 0  0 / 9 (0.00%) 0
Injury, poisoning and procedural complications Fall subjects affected / exposed occurrences (all)  Radius fracture subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1  1 / 8 (12.50%) 1	0 / 39 (0.00%) 0  0 / 39 (0.00%) 0	0 / 9 (0.00%) 0  0 / 9 (0.00%) 0
Nervous system disorders Complex regional pain syndrome subjects affected / exposed occurrences (all)  Dizziness	0 / 8 (0.00%) 0	0 / 39 (0.00%) 0	1 / 9 (11.11%) 2

subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
Paraesthesia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
Taste disorder subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
Eye disorders Eye pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 39 (0.00%) 0	1 / 9 (11.11%) 1
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 2	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 5	0 / 39 (0.00%) 0	1 / 9 (11.11%) 4
Vomiting subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 3	0 / 39 (0.00%) 0	0 / 9 (0.00%) 0
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 3	0 / 39 (0.00%) 0	1 / 9 (11.11%) 2
Renal and urinary disorders Renal pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 39 (0.00%) 0	1 / 9 (11.11%) 3

Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 8 (12.50%)	0 / 39 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Back pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Bone pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Muscle spasms			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Tendonitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Laryngitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Sinusitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Viral upper respiratory tract infection			

subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
<b>Abscess neck</b>			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
<b>Cellulitis</b>			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
<b>Clostridium difficile infection</b>			
subjects affected / exposed	1 / 8 (12.50%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
<b>Lyme disease</b>			
subjects affected / exposed	1 / 8 (12.50%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
<b>Infection protozoal</b>			
subjects affected / exposed	1 / 8 (12.50%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
<b>Pneumonia</b>			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
<b>Diverticulitis</b>			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
<b>Metabolism and nutrition disorders</b>			
<b>Hyperglycaemia</b>			
subjects affected / exposed	1 / 8 (12.50%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
<b>Vitamin D deficiency</b>			
subjects affected / exposed	0 / 8 (0.00%)	0 / 39 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
22 November 2018	The principal changes in this amendment are based on FDA feedback received in September 2018 as well as feedback from ECs, IRBs, and other regulatory authorities. The following changes were implemented: <ul style="list-style-type: none"><li>• Addition of weekly pain intensity assessments after Week 12 using an electronic diary.</li><li>• Clarification of concomitant analgesic medication use as a (non-objective related) outcome.</li><li>• Simplification of the description of "other data to be collected that are not directly attributed to or considered as an endpoint" (there was no change to the planned assessments or evaluations).</li><li>• Removal of specification of male contraception in inclusion criterion 6.</li><li>• Clarification in exclusion criterion 1 that the quoted eGFR and ACR thresholds refer to severe renal impairment.</li></ul>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

A protocol specified interim analysis was conducted on pooled primary endpoint data of trials KF7013-04 and KF7013-02. The interim analysis indicated futility and both trials were stopped.

Notes: